CA2065210A1 - Controlled release matrix for pharmaceuticals - Google Patents

Controlled release matrix for pharmaceuticals

Info

Publication number
CA2065210A1
CA2065210A1 CA2065210A CA2065210A CA2065210A1 CA 2065210 A1 CA2065210 A1 CA 2065210A1 CA 2065210 A CA2065210 A CA 2065210A CA 2065210 A CA2065210 A CA 2065210A CA 2065210 A1 CA2065210 A1 CA 2065210A1
Authority
CA
Canada
Prior art keywords
controlled release
pharmaceuticals
release matrix
matrix
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2065210A
Other languages
French (fr)
Other versions
CA2065210C (en
Inventor
Thinnayam N. Krishnamurthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Thinnayam N. Krishnamurthy
Euroceltique, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thinnayam N. Krishnamurthy, Euroceltique, S.A. filed Critical Thinnayam N. Krishnamurthy
Publication of CA2065210A1 publication Critical patent/CA2065210A1/en
Application granted granted Critical
Publication of CA2065210C publication Critical patent/CA2065210C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories

Abstract

The controlled release of therapeutically active agents is achieved from a controlled release matrix of sodium alginate and a calcium salt. When the composition is to be administered rectally, the matrix is combined with a therapeutically active agent and a suitable suppository base. When the composition is to be administered orally, the matrix further includes a higher aliphatic alcohol.
CA002065210A 1991-09-11 1992-04-06 Controlled release matrix for pharmaceuticals Expired - Lifetime CA2065210C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/758,883 US5215758A (en) 1991-09-11 1991-09-11 Controlled release matrix suppository for pharmaceuticals
US758,883 1991-09-11

Publications (2)

Publication Number Publication Date
CA2065210A1 true CA2065210A1 (en) 1993-03-12
CA2065210C CA2065210C (en) 2000-08-29

Family

ID=25053475

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002065210A Expired - Lifetime CA2065210C (en) 1991-09-11 1992-04-06 Controlled release matrix for pharmaceuticals

Country Status (13)

Country Link
US (2) US5215758A (en)
EP (2) EP0531611B1 (en)
JP (2) JP3034125B2 (en)
KR (2) KR100203339B1 (en)
AT (2) ATE145820T1 (en)
AU (1) AU653048B2 (en)
CA (1) CA2065210C (en)
DE (2) DE69215612T2 (en)
DK (2) DK0531611T3 (en)
ES (2) ES2097826T3 (en)
GR (1) GR3022572T3 (en)
IL (2) IL101758A (en)
ZA (1) ZA923417B (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
EP0652745A1 (en) * 1992-07-31 1995-05-17 Daratech Pty. Ltd. Controlled release implants
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
KR100354702B1 (en) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 Manufacturing method and sustained release composition of pharmaceutical composition
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5554379A (en) * 1994-06-20 1996-09-10 Kv Pharmaceutical Company Long acting GI and esophageal protectant
US5670163A (en) * 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
US5554380A (en) * 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
KR960016882A (en) * 1994-11-01 1996-06-17 강재헌 Sustained-release biodegradable preparations for the treatment of periodontitis
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
KR970064596A (en) * 1996-03-21 1997-10-13 이우용 Hemorrhoid treatment composition for rectal administration
GB9710767D0 (en) * 1996-06-26 1997-07-23 On Ninh Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same
US6093420A (en) * 1996-07-08 2000-07-25 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US5989571A (en) * 1997-07-23 1999-11-23 Millenium Pharmaceutical Technologies, Inc. Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
KR100417489B1 (en) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 Opioid agonist/antagonist combinations
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9816899D0 (en) 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
US6207718B1 (en) 1998-08-07 2001-03-27 Ontogeny, Inc. Pharmaceutical compositions containing hedgehog protein
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
MXPA01005370A (en) * 1999-09-30 2004-05-14 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs.
DK1299104T3 (en) 2000-02-08 2009-08-03 Euro Celtique Sa Oral opioid agonist formulations secured against forgery
IL151058A0 (en) 2000-02-08 2003-04-10 Euro Celtique Sa Controlled-release compositions containing opioid agonist and antagonist
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6720356B2 (en) * 2001-04-20 2004-04-13 Spencer Feldman Magnesium di-potassium EDTA complex and method of administration
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (en) * 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
CA2452871C (en) * 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
JP4256259B2 (en) * 2001-07-18 2009-04-22 ユーロ−セルティーク エス．エイ． Pharmaceutical formulation of oxycodone and naloxone
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002323032B2 (en) 2001-08-06 2005-02-24 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
DK1443912T3 (en) * 2001-10-12 2008-01-21 Elan Pharma Int Ltd Compositions with a combination of immediate and controlled release properties
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
CA2708900C (en) 2002-04-05 2019-06-04 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
AU2003270778B2 (en) 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
JP4808405B2 (en) * 2002-11-26 2011-11-02 ホ−レンベック ギャリ− ア−ル Aqueous sustained-release drug delivery system for highly water-soluble electrolyte drugs
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
WO2005020933A2 (en) * 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
CA2539027C (en) 2003-09-25 2010-02-23 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
EP2298303A1 (en) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
TW201509943A (en) 2004-03-30 2015-03-16 Euro Celtique Sa Oxycodone hydrochloride composition, pharmaceutical dosage form, sustained release oral dosage form and pharmaceutically acceptable package having less than 25 PPM 14-hydroxycodeinone
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
PT1765292T (en) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Abuse-deterrent drug formulations
US9308164B2 (en) 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20070082050A1 (en) * 2005-05-31 2007-04-12 Cherukuri S R Modified release formulations of antihypertensive drugs
KR100730321B1 (en) 2005-09-30 2007-06-19 한국콜마 주식회사 A cosmetic composition of 2 agent and gel patch type for skin lifting, method for manufacturing and using the same
SE530184C2 (en) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesive pharmaceutical film composition containing low viscous alginates
ES2747956T3 (en) * 2005-12-30 2020-03-12 Rdd Pharma Ltd Device to treat anal sphincter
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070286884A1 (en) * 2006-06-13 2007-12-13 Xylos Corporation Implantable microbial cellulose materials for hard tissue repair and regeneration
MX2008016372A (en) 2006-06-19 2009-05-28 Alpharma Inc Pharmaceutical compositions.
AU2007275034A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
CA2709992A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Abuse resistant pharmaceutical compositions of opiod agonists
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
JP6113954B2 (en) * 2008-10-31 2017-04-12 リピッド ファーマシューティカルズ イーエイチエフ． Fatty acids for use as pharmaceuticals
PT2405915T (en) 2009-03-10 2019-01-29 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EP2445481B1 (en) 2009-06-18 2017-03-22 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2012012147A2 (en) 2010-06-30 2012-01-26 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (en) 2010-12-23 2016-09-05 Purdue Pharma Lp Solid oral dosage forms resistant to alterations
KR101946103B1 (en) 2012-07-16 2019-02-08 로드스 테크놀로지즈 Process for improved opioid synthesis
WO2014013311A1 (en) 2012-07-16 2014-01-23 Rhodes Technologies Process for improved opioid synthesis
CN102823585B (en) * 2012-08-28 2014-06-25 中国农业科学院农业环境与可持续发展研究所 Sustained-release preparation for water-soluble pesticide and preparation method of sustained-release preparation
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ES2846735T3 (en) 2013-03-15 2021-07-29 Johnson Matthey Plc Morphine Sulfate Methanolic Solvate, Procedures for Making the Same and Related Compositions, and Pain Treatment Methods
MY183489A (en) 2013-07-23 2021-02-22 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
AU2014298257B2 (en) 2013-08-02 2016-11-10 Macfarlan Smith Limited Process for the preparation of oxymorphone
JP2017502015A (en) * 2013-12-20 2017-01-19 ディスファー・インターナショナル・ベー・フェー Dry enema products
US9932348B2 (en) 2014-01-15 2018-04-03 Rhodes Technologies Process for improved oxycodone synthesis
AU2015207734B2 (en) 2014-01-15 2017-02-23 Rhodes Technologies Process for improved oxymorphone synthesis
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9145420B1 (en) 2015-03-27 2015-09-29 Johnson Matthey Public Limited Company Crystalline forms of morphine sulfate
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPH0684296B2 (en) * 1987-12-21 1994-10-26 花王株式会社 Multi-layer suppository
US5110605A (en) * 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method

Also Published As

Publication number Publication date
ATE145820T1 (en) 1996-12-15
DK0698389T3 (en) 2000-05-01
JP3624123B2 (en) 2005-03-02
DE69215612T2 (en) 1997-05-15
DE69230475T2 (en) 2000-07-13
KR100225493B1 (en) 1999-10-15
CA2065210C (en) 2000-08-29
IL117356A (en) 2000-08-31
DE69215612D1 (en) 1997-01-16
JP2000136149A (en) 2000-05-16
DK0531611T3 (en) 1997-05-26
KR100203339B1 (en) 1999-06-15
DE69230475D1 (en) 2000-01-27
GR3022572T3 (en) 1997-05-31
IL101758A (en) 1996-12-05
IL117356A0 (en) 1996-07-23
EP0531611A1 (en) 1993-03-17
AU2107392A (en) 1993-03-18
ZA923417B (en) 1993-01-27
IL101758A0 (en) 1992-12-30
ES2097826T3 (en) 1997-04-16
US5215758A (en) 1993-06-01
EP0698389A1 (en) 1996-02-28
JPH05148159A (en) 1993-06-15
AU653048B2 (en) 1994-09-15
ES2139798T3 (en) 2000-02-16
JP3034125B2 (en) 2000-04-17
EP0531611B1 (en) 1996-12-04
KR930005616A (en) 1993-04-20
US5508043A (en) 1996-04-16
EP0698389B1 (en) 1999-12-22
ATE187887T1 (en) 2000-01-15

Similar Documents

Publication Publication Date Title
AU2107392A (en) Controlled release matrix for pharmaceuticals
PT781550E (en) BIOADHESIVE PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED LIBERATION OF ACTIVE PRINCIPLES
IL111519A (en) Sustained release tablets containing acetaminophen and methods for the preparation thereof
DE3583799D1 (en) SOLID PREPARATION WITH SLOW RELEASE.
DK0695172T3 (en) Fast-release solid preparation, its preparation and its use
AU585775B2 (en) Self controlled release device for administering beneficial agent to recipient
EA200100541A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED SURVIVAL OF THE SENSITIZER TO INSULIN AND OTHER ANTI-DIABETIC AGENTS
CA2113916A1 (en) 6-Chloro-5-Fluoro-3-(2-Thenoyl)-2-Oxindole-1-Carboxamide as an Analgesic and Anti-Inflammatory Agent
CA2231176A1 (en) Long active composition for rectal administration
SE8800025D0 (en) BIOADHESIVE SUPPOSITORY PHARMACEUTICAL PREPARATIONS
EP0754456A3 (en) Topical application of ST1435 as a contraceptive agent
ES2014518A6 (en) Sustained release composition
DK0522122T3 (en) Pharmaceuticals containing amethocaine
MX9500231A (en) 4-arylisoindole analgesics.
SE8704240D0 (en) ANALGESIC PREPARATIONS
KR900016130A (en) 2-pyridylmethylthio derivatives and ulcer treatments
ATE102934T1 (en) FLUORINATED FLAVONACETIC ACID.
DK493887A (en) BUCCAL FORMULATION

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry